Published online Jul 16, 2021. doi: 10.12998/wjcc.v9.i20.5442
Peer-review started: January 19, 2021
First decision: April 15, 2021
Revised: April 20, 2021
Accepted: May 19, 2021
Article in press: May 19, 2021
Published online: July 16, 2021
Processing time: 169 Days and 3.3 Hours
Dermatofibrosarcoma protuberans (DFSP) is a rare skin and soft tissue malignant tumor with low grade, accounting for 1% of all soft tissue malignant tumors. The tumor has a high recurrence rate after operation.
To evaluate the clinical manifestations, pathological features, and immune molecules of DFSP, and identify risk factors that may be related to prognosis.
To clarity whether there are some clinical or pathological features related to prognosis of DFSP.
This study is a retrospective analysis. We analyzed the tumor size, treatment experience, operation scope, and other dimensions, and quantified the relevant information. SPSS21.0 statistical software was adopted for statistical analyses.
A total of 44 patients with DFSP were included and 42 cases were followed, of whom four experienced relapse, with a recurrence rate of 9.52%. For patients with a previous history of recurrence, the recurrence risk was higher than that in the patients with primary tumor (19.05% vs 0% P = 0.028). The recurrence risk in those patients with misdiagnosis experience was higher than that in the patients without (68% vs 36.84%, P = 0.04). The tumor diameter in patients with treatment history was larger than that in patients treated for the first time (4.75 ± 0.70 cm vs 2.25 ± 0.36 cm, P = 0.004).
Tumor location and previous treatment history have an impact on the prognosis of the disease. However, the above factors indirectly affect the prognosis by affecting the extent of surgical resection. Repeated and incomplete treatment can lead to the enlargement of the tumor, which in turn affects the scope of surgical resection. In addition, no immune markers related to postoperative recurrence was found.
In the future, we will continue to follow all patients to analyze the causes of death and the risk factors that may lead to death. And we will devote ourselves to finding immune markers related to the prognosis of patients with DFSP.